Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Long-Term Debt Repayments (2020 - 2022)

Insight Molecular Diagnostics' Long-Term Debt Repayments history spans 3 years, with the latest figure at $575000.0 for Q3 2022.

  • For Q3 2022, Long-Term Debt Repayments rose 53.33% year-over-year to $575000.0; the TTM value through Dec 2022 reached $1.3 million, down 11.67%, while the annual FY2022 figure was $1.3 million, 11.67% down from the prior year.
  • Long-Term Debt Repayments for Q3 2022 was $575000.0 at Insight Molecular Diagnostics, up from $375000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $575000.0 in Q3 2022 and bottomed at $250000.0 in Q4 2020.
  • The 3-year median for Long-Term Debt Repayments is $375000.0 (2021), against an average of $384375.0.
  • The largest YoY upside for Long-Term Debt Repayments was 53.33% in 2022 against a maximum downside of 0.0% in 2022.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $250000.0 in 2020, then soared by 50.0% to $375000.0 in 2021, then skyrocketed by 53.33% to $575000.0 in 2022.
  • Per Business Quant, the three most recent readings for IMDX's Long-Term Debt Repayments are $575000.0 (Q3 2022), $375000.0 (Q2 2022), and $375000.0 (Q1 2022).